Boxer Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-600,000
Closed -$20.1M – 33
2025
Q1
$20.1M Hold
600,000
– – 6.05% 6
2024
Q4
$23.5M Hold
600,000
– – 2% 12
2024
Q3
$23.6M Hold
600,000
– – 1.16% 24
2024
Q2
$23.4M Hold
600,000
– – 1.23% 25
2024
Q1
$25.8M Hold
600,000
– – 1.28% 23
2023
Q4
$27.6M Hold
600,000
– – 1.38% 23
2023
Q3
$20.5M Hold
600,000
– – 1.09% 31
2023
Q2
$23.1M Hold
600,000
– – 1.07% 33
2023
Q1
$21.5M Hold
600,000
– – 1.05% 32
2022
Q4
$23.7M Hold
600,000
– – 1.25% 30
2022
Q3
$21.7M Hold
600,000
– – 1.22% 30
2022
Q2
$18.3M Hold
600,000
– – 1.16% 30
2022
Q1
$18.3M Hold
600,000
– – 0.94% 34
2021
Q4
$18.7M Sell
600,000
-257,000
-30% -$7.68M 0.73% 32
2021
Q3
$13.1M Hold
857,000
– – 0.46% 55
2021
Q2
$16M Buy
+857,000
New +$15.8M 0.56% 54
2020
Q4
– Sell
-600,000
Closed -$6.64M – 86
2020
Q3
$6.64M Hold
600,000
– – 0.23% 62
2020
Q2
$7.52M Hold
600,000
– – 0.33% 50
2020
Q1
$6.8M Buy
+600,000
New +$8.54M 0.46% 46
2018
Q4
– Sell
-300,000
Closed -$3.96M – 28
2018
Q3
$3.96M Buy
+300,000
New +$3.48M 0.44% 20

Other funds holding XENE

Boxer Capital Management's XENE Position: Q2 2025 in Review

Boxer Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 600,000 shares — an estimated $20.1M sold.

Boxer Capital Management first reported a position in XENE in Q3 2018 and held it in 20 quarters. The position peaked at $27.6M in Q4 2023. 207 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Boxer Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Boxer Capital Management sold 600,000 Xenon Pharmaceuticals shares in Q2 2025, an estimated $20.1M.
  • Boxer Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 20 quarters.
  • Boxer Capital Management's Xenon Pharmaceuticals position peaked at $27.6M in Q4 2023.
  • 207 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Boxer Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.